133 related articles for article (PubMed ID: 19856059)
1. Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Hasegawa Y; Mita K; Matsubara A; Ohdan H
Int J Clin Oncol; 2009 Oct; 14(5):465-7. PubMed ID: 19856059
[TBL] [Abstract][Full Text] [Related]
2. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Zołnierek J; Nurzyński P; Langiewicz P; Oborska S; Waśko-Grabowska A; Kuszatal E; Obrocka B; Szczylik C
J Cancer Res Clin Oncol; 2010 Mar; 136(3):371-8. PubMed ID: 19711099
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Negrier S; Jäger E; Porta C; McDermott D; Moore M; Bellmunt J; Anderson S; Cihon F; Lewis J; Escudier B; Bukowski R
Med Oncol; 2010 Sep; 27(3):899-906. PubMed ID: 19757215
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Reddy GK; Bukowski RM
Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a brain-metastasized renal cell carcinoma.
Walid MS; Johnston KW
Ger Med Sci; 2009 Oct; 7():Doc28. PubMed ID: 19911072
[TBL] [Abstract][Full Text] [Related]
11. [Radiotherapy in treatment of relapsing renal cell cancer].
Metelev VV; Zharinov GM
Vopr Onkol; 2008; 54(6):775-7. PubMed ID: 19241859
[No Abstract] [Full Text] [Related]
12. Choroidal metastasis of renal cell carcinoma: a case report.
Kurashige Y; Otani A; Yoshimura N
Jpn J Ophthalmol; 2010 Jan; 54(1):111-2. PubMed ID: 20151293
[No Abstract] [Full Text] [Related]
13. [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Arima S; Shiroki R; Mori S; Maruyama T; Sasaki H; Kusaka M; Miyakawa S; Hayakawa K; Hoshinaga K
Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):660-5. PubMed ID: 18697474
[TBL] [Abstract][Full Text] [Related]
14. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Verzoni E; Lanocita R; Procopio G
Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
[No Abstract] [Full Text] [Related]
15. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Flaherty KT
Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
[No Abstract] [Full Text] [Related]
16. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
17. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Beck J; Bellmunt J; Escudier B
Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
[TBL] [Abstract][Full Text] [Related]
19. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
20. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Wendel C; Campitiello M; Plastino F; Eid N; Hennequin L; Quétin P; Longo R
Am J Case Rep; 2017 Jan; 18():7-11. PubMed ID: 28044054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
